0001096906-22-000128.txt : 20220215 0001096906-22-000128.hdr.sgml : 20220215 20220114170354 ACCESSION NUMBER: 0001096906-22-000128 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mycotopia Therapies, Inc. CENTRAL INDEX KEY: 0001763329 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-GROCERIES & GENERAL LINE [5141] IRS NUMBER: 870645794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 480 22ND STREET CITY: HEYBURN STATE: ID ZIP: 83336 BUSINESS PHONE: 208-677-2020 MAIL ADDRESS: STREET 1: 480 22ND STREET CITY: HEYBURN STATE: ID ZIP: 83336 FORMER COMPANY: FORMER CONFORMED NAME: 20/20 Global, Inc. DATE OF NAME CHANGE: 20190102 CORRESP 1 filename1.htm

January 14, 2022

United States Securities

and Exchange Commission

Division of Corporation Finance

Office of Trade & Services

Attn: Ryan Lichtenfels

Washington, D.C. 20549

 

Re: Mycotopia Therapies, Inc. 

Form 1-A

Filed January 6, 2022

File No. 024-11770

 

Dear Mr. Lichtenfels:

Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), Mycotopia Therapies, Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") issue a qualification order for the above referenced Offering Statement on Form 1A, so that it may be qualified by 4:00 pm., Eastern Time on Tuesday, January 18, 2022, or as soon thereafter as is practicable.

We understand that the Commission has completed its review and has no further comments.

The Company is aware of its responsibilities under the Act, as they relate to this offering of securities. As requested, the Company further acknowledges that:

·Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing; 

·The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its responsibility for the adequacy and accuracy of the disclosures in the filing; and 

·The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. 

The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

If you have any questions, please contact our counsel, Jonathan Leinwand (954) 903-7856.

Thank you in advance for your assistance.

Very Truly Yours,

MYCOTOPIA THERAPIES, INC.

By:/s/ Ben Kaplan  

     Ben Kaplan, CEO